Antibody-targeted paclitaxel loaded nanoparticles for the treatment of CD20(+) B-cell lymphoma

We developed a nano-antibody targeted chemotherapy (nATC) delivery strategy in which tumor specific and clinically relevant antibodies (rituximab, anti-CD20) are non-covalently bound to the albumin scaffold of nab-paclitaxel (ABX). We define the nanoparticle formed when the 2 drugs are bound (AR160)...

Descripción completa

Detalles Bibliográficos
Autores principales: Nevala, Wendy K., Butterfield, John T., Sutor, Shari L., Knauer, Daniel J., Markovic, Svetomir N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5381215/
https://www.ncbi.nlm.nih.gov/pubmed/28378801
http://dx.doi.org/10.1038/srep45682

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5381215/
https://www.ncbi.nlm.nih.gov/pubmed/28378801
http://dx.doi.org/10.1038/srep45682

Ejemplares similares